Neuropathic pain and its treatment with ARA 290 and ketamine : overlapping pathways

Leiden Repository

Neuropathic pain and its treatment with ARA 290 and ketamine : overlapping pathways

Title: Neuropathic pain and its treatment with ARA 290 and ketamine : overlapping pathways
Author: Swartjes, Maarten
Publisher: Department of Anesthesiology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
Issue Date: 2014-06-12
Keywords: Neuropathic pain
ARA 290
Ketamine
Norketamine
Traxoprodil
Small fiber neuropathy
Abstract: Neuropathic pain is a disabling disease with a mechanism consisting of several pathways that ultimately converge in the development and persistence tactile and cold allodynia. Pharmacological treatment is often inadequate and coincides with intolerable side effects. The spared nerve injury animal model of neuropathic pain was employed as a method for evaluating the effect of the 11-amino acid tissue protective peptide ARA 290, and the NMDA receptor antagonist ketamine on behavioral and cellular responses after nerve injury and comparison of these two drugs. Clinically, pain is a subjective outcome that can be measured by numerical rating scales or questionnaires. Due to this subjectiveness it is not reliable for diagnosing small fiber neuropathy (SFN). Therefore, SFN is being diagnosed by invasive method of intra-epidermal nerve fiber density evaluated with microscopy. Alternatively, the cornea has a high density of small nerve fibers that can be evaluated by the non-invasive method of corneal confocal microscopy. Finally, the effect of ARA 290 on nerve fiber loss and corneal nerve fiber density in sarcoidosis patients in a double-blind-randomized clinical study was evaluated that showed that ARA 290 is a potential disease modifying agent for treatment of sarcoidosis-associated SNFLD.
Description: Promotor: A. Dahan, Co-Promotor: E.Y. Sarton
With Summary in Dutch
Faculty: LUMC
Citation: Swartjes, M., 2014, Doctoral Thesis, Leiden University
ISBN: 9789461695093
Sponsor: Araim Pharmaceuticals
Handle: http://hdl.handle.net/1887/25983
 

Files in this item

Description Size View
application/pdf Full Text 9.904Mb View/Open
text/html Links to published articles 37.66Kb View/Open
application/pdf Cover 87.84Kb View/Open
application/pdf Title Pages_Contents 88.48Kb View/Open
application/pdf Chapter 1 179.0Kb View/Open
application/pdf Chapter 2 431.7Kb View/Open
application/pdf Chapter 3 1.419Mb View/Open Full text at publisher site
application/pdf Chapter 4 4.165Mb View/Open Full text at publisher site
application/pdf Chapter 5 1.350Mb View/Open Full text at publisher site
application/pdf Chapter 6 1.114Mb View/Open Full text at publisher site
application/pdf Chapter 7 753.0Kb View/Open
application/pdf Chapter 8 741.0Kb View/Open Full text at publisher site
application/pdf Summary in English 108.9Kb View/Open
application/pdf Summary in Dutch 112.5Kb View/Open
application/pdf Curriculum Vitae_Publications 82.36Kb View/Open
application/pdf Propositions 137.6Kb View/Open

This item appears in the following Collection(s)